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Objective: Recently, the characteristic longitudinal distribution pattern of the underlying
phosphorylated TDP-43 (pTDP-43) pathology in the behavioral variant of frontotemporal
dementia (bvFTD) excluding Pick’s disease (PiD) across specific brain regions was
described. The aim of the present study was to investigate whether in vivo investigations
of bvFTD patients by use of diffusion tensor imaging (DTI) were consistent with these
proposed patterns of progression.
Methods: Sixty-two bvFTD patients and 47 controls underwent DTI in a multicenter
study design. Of these, 49 bvFTD patients and 34 controls had a follow-up scan after
∼12 months. Cross-sectional and longitudinal alterations were assessed by a two-fold
analysis, i.e., voxelwise comparison of fractional anisotropy (FA) maps and a tract of
interest-based (TOI) approach, which identifies tract structures that could be assigned
to brain regions associated with disease progression.
Results: Whole brain-based spatial statistics showed white matter alterations
predominantly in the frontal lobes cross-sectionally and longitudinally. The TOIs of
bvFTD neuroimaging stages 1 and 2 (uncinate fascicle—bvFTD pattern I; corticostriatal
pathway—bvFTD pattern II) showed highly significant differences between bvFTD
patients and controls. The corticospinal tract-associated TOI (bvFTD pattern III) did not
differ between groups, whereas the differences in the optic radiation (bvFTD pattern IV)
reached significance. The findings in the corticospinal tract were due to a “dichotomous”
behavior of FA changes there.
Conclusion: Longitudinal TOI analysis demonstrated a pattern of whitematter pathways
alterations consistent with patterns of pTDP-43 pathology.
Keywords: frontotemporal lobar degeneration, diffusion tensor imaging, fractional anisotropy, neuropathology,
staging
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INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is the second most
frequent cause of dementia and, in individuals under 65
years of age, its prevalence is similar to that of Alzheimer’s
disease (Rosso et al., 2013). The neuropathological hallmarks
of a large proportion of FTLD cases are neuronal cytoplasmic
inclusions and dystrophic neurites that are immunoreactive for
ubiquitin, p62, and the phosphorylated 43-kDa TAR DNA-
binding protein (pTDP-43), which is also the major disease
protein in amyotrophic lateral sclerosis (Neumann et al., 2006).
The progressive accumulation of inclusions formed by disease-
specific protein aggregates is typical of many neurodegenerative
diseases, including sporadic Alzheimer’s disease and sporadic
Parkinson’s disease (Jucker and Walker, 2013; Goedert, 2015;
Walker and Jucker, 2015). Importantly, in postmortem studies,
many of these disorders reveal a characteristic distribution
pattern of their underlying pathology across specific brain
regions with disease progression, as was recently proposed
for pTDP-43 proteinopathies (Brettschneider et al., 2013,
2014; Josephs et al., 2014). These findings may permit the
categorization of longitudinal disease progression into disease
stages in a clinical setting (bvFTD stages). Although challenging,
the transfer of neuropathological findings into a clinical setting
could make individual diagnostic procedures possible and
encourage its use as a potential surrogate marker of disease to
achieve substantial cost-savings and increase the feasibility of
clinical trials (McMillan et al., 2014). Recently, we demonstrated
that progressive regional accumulation of pTDP-43 inclusions
in ALS reflects sequential involvement of white matter fiber
tracts of the central nervous system (Kassubek et al., 2014,
2017; Müller et al., 2016). While no direct neuroimaging marker
for pTDP-43 exists at present, several earlier neuropathological
studies have emphasized the close correlation between the
severity of pTDP-43 aggregation and neuro-axonal loss (Geser
et al., 2008, 2009). Behavioral variant frontotemporal dementia
(bvFTD), the main FTLD subtype, is characterized by progressive
decline of executive function and inappropriate social conduct
(Rascovsky et al., 2011). Four neuropathological patterns of
pTDP-43 pathology were recently identified in a cohort of 39
autopsy cases excluding Pick’s disease (PiD) (Brettschneider et al.,
2014). Consistent with the hypothesis of sequential progression
and propagation along axonal pathways, the four regional
distribution patterns of pTDP-43 pathology included: (I) basal
and anterior portions of the prefrontal neocortex (orbital gyri,
gyrus rectus, inferior frontal gyrus), (II) prefrontal neocortical
areas (middle frontal gyrus, insular cortex, and anterior cingulate
gyrus), anteromedial temporal areas (transentorhinal region),
the superior and middle temporal gyri, striatum, red nucleus,
medial and lateral portions of the thalamus, and precerebellar
nuclei of the brainstem, (III) the agranular motor neocortex,
parietal neocortical areas (sensory cortex, angular gyrus), bulbar
somatomotor neurons, and (IV) the occipital neocortex. In the
current study, fiber tracking with a tract of interest (TOI)-
based approach was applied to a cohort of bvFTD patients and
control individuals both cross-sectionally and longitudinally to
analyze involved major white matter pathways and to test the
hypothesis that a pattern corresponding to those areas seen at
autopsy during staging could be confirmed in vivo. The aim of
this study was two-fold: (1) based on longitudinal DTI data,
microstructural longitudinal alterations should be detectable in
the course of bvFTD. (2) Based on previous neuropathological
findings and on the in vivo microstructural cross-sectional and
longitudinal alteration and progression patterns, (2) it should be
possible to propose a staging protocol using a tract-based DTI
analysis that allows for an individual staging analysis for bvFTD
patients.
METHODS
Subjects and MRI Acquisition
Sixty-two patients with a clinical diagnosis of bvFTD according
to established diagnostic criteria (Rascovsky et al., 2011) as
made by specialized board-certified neurologists were included
in this study, together with 49 controls. Data acquisition was
performed at three study sites (Ulm and Leipzig, Germany;
Sydney, Australia). The study was approved by the local
ethics committees (Ethics Committee of the University of Ulm
(39/11); Ethics Committee of the University of Leipzig (137-
11-18042011); Human Ethics Committees of South Eastern
Sydney and Illawarra Area Health Service and the University of
New South Wales), and written informed consent was obtained
from each participant or the primary caregiver in accordance
with the Declaration of Helsinki. Demographic data are shown
in Table 1. BvFTD was diagnosed after clinical examination,
neuropsychological testing, and MRI findings, according to the
criteria of the Lund-Manchester Group (Neary et al., 1988; The
Lund and Manchester groups, 1994) and the Work Group on
Frontotemporal Dementia and Pick’s Disease (McKhann et al.,
2001). Patients with bvFTD displayed progressive behavioral
abnormalities with an early loss of personal and social insight
and, inMRI, symmetrical or asymmetrical atrophy in the anterior
temporal lobes, prefrontal lobes, or both.
The bvFTD patients and controls from all centers underwent
MR scanning on 3.0T scanners (Sydney: 3.0T Philips; Leipzig:
Verio, Siemens Medical; Ulm: Allegra, Siemens Medical).
Accordingly, DTI data were acquired using three different
protocols. The Ulm DTI protocol consisted of 31 gradient
directions (GD), including one b = 0 GD (80 slices, 112 × 128
pixels; slice thickness was 2.0mm, in-plane pixel size was 2.0
× 2.0mm). The echo time (TE) and repetition time (TR) were
88 and 11100ms; b was 1000 s/mm2. The Leipzig DTI protocol
consisted of 67 GD, including 7 b = 0 GD (80 slices, 128 × 128
pixels; slice thickness was 1.7mm, in-plane pixel size was 1.7 ×
1.7mm); TE and TR were 100 and 15200ms; b was 1000 s/mm2.
The SydneyDTI protocol consisted of 34 GD, including one b= 0
GD (55 slices, 96× 96 pixels; slice thickness was 2.5mm, in-plane
pixel size was 2.5× 2.5mm); TE and TR were 68ms and 8400ms;
b was 500 s/mm2.
During a follow-up scan with a time-interval of 12 months
(range 10–41 months), 49 of the 62 bvFTD patients received a
DTI scan that allowed further analysis; 34 of the 47 controls
received a follow-up scan with a time-interval of 20 months
(range 12 to 59 months). The remaining 13 patients were not
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TABLE 1 | Demographic parameters for bvFTD patients (N = 62) and controls (N = 47).
N N (follow-up) Age/years Gender (m/f) Disease duration/years MMSE
Ulm, Germany
bvFTD 18 10 65 ± 11 7/11 3 ± 2 25 ± 5
Controls 15 6 63 ± 12 9/6 n.a. n.a.
Leipzig, Germany
bvFTD 10 5 62 ± 13 5/5 6 ± 8 24 ± 4
Controls 7 3 61 ± 6 3/4 n.a. n.a.
Sydney, Australia
bvFTD 34 34 62 ± 8 23/11 5 ± 3 n.av.
Controls 25 25 69 ± 7 11/14 n.a. n.a.
Sum
bvFTD 62 49 63 ± 10 35/27 5 ± 4 24 ± 5
Controls 47 34 66 ± 9 23/24 n.a. n.a.
P > 0.05 > 0.05
Values are given in mean (± standard deviation). MMSE, Mini-Mental-State-Examination (MMSE) (Folstein et al., 1975), n.a., not applicable; n.av. not available. p was calculated by
Mann-Whitney test.
available for a second MRI investigation due to inconveniences
caused by long travel.
Standardized Data Pre-Processing
The DTI analysis software Tensor Imaging and Fiber Tracking
(TIFT) (Müller et al., 2007a, 2013) was used for pre-/post-
processing and statistical analysis.
Data Processing I: MNI Normalization
After motion correction of individual DTI data sets, in a first step,
baseline DTI and follow-up DTI data were aligned by fitting of
the (b = 0)-volumes (intensity difference minimization); here,
halfway linear registration matrices (Menke et al., 2014) were
applied to avoid a bias of the baseline data. Consequently, the
following stereotaxicMNI transformation of baseline and follow-
up data were performed with the identical parameters.
Spatial normalization to the Montreal Neurological Institute
(MNI) stereotaxic standard space was performed (Brett et al.,
2002; Figure 1A): The normalization process was iterative, using
a study-specific (b = 0)-template and additionally a fractional
anisotropy (FA)-template at each iteration step, since an FA-
template has more contrast in comparison to (b = 0)-images
(Smith et al., 2006). In the first iteration step, a normalization by a
linear transformation according to manually set landmarks leads
to a first study-specific (b = 0)-template and to an FA-template
by arithmetically averaging the (b = 0)-volumes and FA maps,
respectively. To optimize the normalization matrices, improved
templates could be created in a second iteration step from the
normalized DTI data by a non-linear MNI normalization of the
DTI data sets (non-linear minimization of the mismatch between
regional intensities of the FA-map to be fitted and of the FA-
template according to the squared differences). The correlation
between individual FA-maps and the FA-template is > 0.7 after
two iterations so that the iterative process was stopped after two
iterations (Müller and Kassubek, 2013).
After each iteration step, a systematic between-center
adjustment was performed (see section “Data processing V”)
prior to creation of the study specific templates. Directional
information during the normalization process was preserved
according to techniques described by Alexander et al. (2001)
(Müller et al., 2009).
Finally, a Gaussian smoothing filter of 8mm full width at
the half maximum (FWHM) was applied to the individual
normalized FA-maps. The filter size of 8mm (which is about
2–3 times the recording voxel size, depending on the protocol)
provides a good balance between sensitivity and specificity
(Müller et al., 2013).
Data Processing II: Definition of Tract Structures
To apply group-based fiber tracking (FT) algorithms (Müller
et al., 2009), an averaged DTI data set was calculated from 25
control data sets with the identical DTI protocol by arithmetic
averaging of the MNI transformed data. For each voxel position,
Eigenvectors and Eigenvalues were calculated that represented
the average of all controls’ data sets. For this averaged DTI data
set, only controls’ data sets were used because the reconstruction
of the pathways could be biased if voxels with pathology-
induced alterations would contribute to the averaged data set.
Directional information of each data set was preserved during
the normalization process and was incorporated in the template
creation (Müller et al., 2009).
This averaged DTI data set from controls was then used to
identify pathways for defined brain structures according to the
previously proposed neuropathological patterns (Brettschneider
et al., 2014) with a seed-to-target approach (Kassubek et al., 2014,
2017). For this purpose, regions of interest (ROIs) were defined
for the seed and target regions. For fiber tracking, only voxels
with an FA value above a threshold of 0.2 were considered. All
fiber tracts (FTs) originating in the seed ROI and ending in the
target ROI of the respective pathway define the corresponding
TOI. For the fiber tracking technique, a modified deterministic
streamline tracking approach was used that takes the directional
information of neighbored FTs into account (Müller et al., 2009).
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FIGURE 1 | (A) Data analysis scheme. (i) To obtain a common coordinate frame, baseline and follow-up DTI data were aligned by half-way correction. (ii) After
landmark normalization, study-specific b0 and FA templates were created. (iii) DTI data of all visits were stereotaxically normalized in the Montreal Neurological Institute
(MNI) coordinate frame in an iterative process. Then, the voxelwise statistical comparison between the patients and the control group was performed by whole brain
based spatial statistics (WBSS). After averaging controls’ data sets, fiber tracts were calculated from this averaged data set. Finally, tractwise fractional anisotropy
statistics (TFAS) was applied. (B) Decision algorithm for categorization. From all bvFTD patients, those were further analyzed who had z-transformed TOI-FA
values < 0, i.e., TOI-FA values below the FA-threshold defined for the uncinate fascicle (bvFTD-stage 1). Of this group, those were defined for bvFTD-stage 1 who
had z-transformed TOI-FA-values > 0 in the corticostriatal pathway, and those were defined for bvFTD-stage 2 who had z-transformed TOI-FA-values > 0 in the
corticospinal tract. The remaining individuals were categorized into bvFTD-stages 3 or 4, depending on whether their z-transformed TOI-FA-values in the optic
radiation were > 0 or < 0.
The specific pathogenic mechanisms underlying bvFTLD
are still largely unknown; however, studies of anatomical
connectivity provide evidence for white matter impairment in
bvFTD (Mahoney et al., 2014, 2015; Tovar-Moll et al., 2014). For
this reason, it appeared conceptually reasonable to choose, tracts
that might reflect the hypothetical “progression” of the pathology
along anatomical pathways (axons) in relationship to relevant
regions of the brain:
Pattern 1: TDP-43 pathology develops in projection neurons
of basal and anterior portions of the prefrontal neocortex (orbital
gyri, gyrus rectus, and inferior frontal gyrus). We opted for the
uncinate fascicle, in part, based on the previous findings there in
bvFTD by other groups (Mahoney et al., 2014, 2015; Tovar-Moll
et al., 2014).
Pattern 2: This pattern is marked by the development of
pathology in the middle frontal gyrus, insular cortex, anterior
cingulate gyrus, the superior and middle temporal gyri, ventral
striatum (accumbens nucleus), the parvocellular portion of the
red nucleus, in medial and lateral portions of the thalamus,
the inferior olivary complex, but also in anteromedial portions
of the temporal lobe: transentorhinal and entorhinal regions),
including the hippocampal formation (dentate fascia, Ammon’s
horn sectors 1-2).
Pattern 3: The chief structures affected are the agranularmotor
cortex and functionally linked motor neurons in the brainstem
and spinal cord ventral horn. Thus, the corticospinal tract (CST)
was the logical tract of choice.
Pattern 4: The greatest burden of TDP-43 pathology occurred
in the occipital neocortex (visual cortex, Brodmann 17, 18) in
addition to involvement of all of the regions affected in the
previous three patterns. It should be pointed out that the visual
cortex either was not examined in detail or at all in early (pre-
TDP-43) post-mortem studies of frontotemporal degenerative
disorders (e.g., see Mann et al., 1993; The Lund and Manchester
groups, 1994; Giannakopoulos et al., 1995). The optic radiation
was considered a suitable choice to represent this pattern.
Figure 2 shows the representative TOIs for the definition of
the four bvFTD patterns: (I) the frontal part of the uncinate
fascicle, (II) the corticostriatal pathway, (III) the corticospinal
tract (CST), and (IV) the optic radiation (Brettschneider et al.,
2014). Additionally, the superior cerebellar peduncle was defined
as a reference path where no involvement in bvFTD-associated
neurodegeneration could be anticipated. TOI coordinates are
summarized in Table 2.
Data Processing III: Tract-Wise Fractional Anisotropy
Statistics
The technique of tract-wise fractional anisotropy statistics
(TFAS) (Müller et al., 2007b) was applied to quantify the
tractography results by use of the TOI. The FA values
underlying the specific tracts were arithmetically averaged for
each stereotaxically normalized DTI data set of each subject.
The TOIs that were defined for the four bvFTD patterns, each
being neuropathologically defined as becoming involved in a
given sequence (Brettschneider et al., 2014), build the basis
for “bvFTD-stage”-related results, i.e., FA values underlying the
bihemispheric uncinate fascicle were averaged to “bvFTD-stage
Frontiers in Aging Neuroscience | www.frontiersin.org 4 March 2018 | Volume 10 | Article 47
Kassubek et al. DTI-Based Progression Patterns in bvFTD
FIGURE 2 | (A) 3D-images of tracts of interest. 3D-images of tracts of interest: fasciculus uncinatus, corresponding to bvFTD stage 1; corticostriatal pathway,
corresponding to bvFTD stage 2; corticospinal tract (CST) corresponding to bvFTD stage 3, optic radiation, corresponding to bvFTD stage 4; superior cerebellar
peduncle as reference path. (B) Longitudinal FA differences in stage-related tract systems. Longitudinal averaged FA differences (baseline—follow-up) in tracts at the
group level—*significance.
1”-related results, and an analogous procedure was applied to the
TOIs corresponding to the other three bvFTD-patterns.
Data Analysis of Longitudinal Differences
Data Processing IV: Comparison of Longitudinal
Alterations at the Group Level
The FA differences between follow-ups and the baseline in the
TOIs of bvFTD patients and controls were directly calculated
from MNI-normalized data with prior alignment of baseline and
follow-up DTI data (halfway linear registration, Menke et al.,
2014). With the assumption that the alteration process is linear,
the differences in FA-values were then linearly corrected to the
identical time interval of 12 months prior to the comparison
at the group level (Kassubek et al., 2017). Differences in FA-
values were linearly normalized for each subject (bvFTD patients
and controls) to an identical time-interval prior to statistical
comparison.
1FA = (FA(t1)− FA(t2))/(t1 − t2)
∗1d (1)
t1 and t2 are the timepoints of baseline and follow-up scans.
In this manner, variable follow-up durations were
compensated for, especially the (at average) longer follow-
up durations of controls. Note that these differences include the
normal aging within the time interval of 12 months.
Cross-Sectional Data Analysis at the
Group Level
Data Processing V: Whole Brain-Based Spatial
Statistics
Different factors may contribute to the variability of DTI data
of bvFTD patients and control subjects. The analysis of group
TABLE 2 | Tract-of-interest (TOI) based fiber tracking (FT).
Tract Seed ROI Target ROI
Fasciculus uncinatus bvFTD-stage 1 ±39/-1/-23 ±14/48/-5
Corticostriatal path bvFTD-stage 2 ±23/22/12 ±13/38/36
Corticospinal tract bvFTD-stage 3 ±27/-18/18 ±19/-40/58
Optic radiation bvFTD-stage 4 ±45/-40/-3 ±26/-82/2
Superior cerebellar peduncle reference 0/-29/-25 ±27/-67/-42
Montreal Neurological Institute (MNI) coordinates for seed and target ROIs for the
respective FTs for the TOI approach. ROI sizes were 10mm for all seed ROIs and 20mm
for all target ROIs.
FA differences between controls on systematic between-center
differences was used to adjust for these differences in order to
make pooling across centers feasible. First, the covariates age
and voxel size were regressed out in FA maps of controls, and
a corrected FA-map set consisting of FA maps of all controls
was calculated. In a second step, a comparison of FA maps
of controls samples was performed between centers, and 3-D
linear correction matrices were calculated (Rosskopf et al., 2015).
Finally, the covariates age and voxel size were regressed out, and
the 3-D linear correction matrices were applied to the FA maps
of all controls and bvFTD patients from each center to obtain
center-harmonized FA maps. This procedure has already been
successfully applied to a multicenter data analysis from eight sites
(Müller et al., 2016).
WBSS between the patient group and the controls was
performed in protocol-harmonized and age-corrected FA maps
by Student’s t-test (Müller et al., 2016). FA values below 0.2 were
not considered for calculation (cortical gray matter shows FA
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values up to 0.2) because this is the most reliable method to
distinguish between white and gray matter FA values (Kunimatsu
et al., 2004;Müller et al., 2012). The next steps were the correction
for multiple comparisons using the false-discovery-rate (FDR)
algorithm (Genovese et al., 2002) at p < 0.05 and a clustering
procedure for further reduction of type I and type II errors with
a threshold cluster size of 256 voxels (Müller et al., 2013).
bvFTD Staging
Data Processing VI: bvFTD Staging
Single subject results for each of the pathways was performed
by TFAS. For each DTI data set (of each subject), an averaged
FA value for each TOI was obtained. Following the previously
reported analysis procedure (Kassubek et al., 2014), optimum
group separation (optimization of sensitivity and specificity for
group separation in the primary affected tract structure, i.e., the
frontal part of the uncinate fascicle), was obtained at an FA-
threshold of µ-0.47σ and was chosen to categorize the disease
stage between bvFTD subjects and controls (Kassubek et al.,
2014). By application of analogous thresholds (µ-0.47σ) for TFAS
to the remaining tract systems, this categorization into the staging
scheme (“bvFTD stage 1” to “bvFTD stage 4”) was performed
after z-transformation of FA results to the respective FA threshold
(defined separately for each TOI structure; Figure 1B): bvFTD
patients who had z-transformed TOI-FA values < 0 in the
TOI of the respective bvFTD stage were further analyzed for
the following bvFTD stages, i.e., TOI-FA values below the FA-
threshold defined for the frontal part of the uncinate fascicle
(related to bvFTD stage 1). Of this group, those were defined
for bvFTD stage 1 who had z-transformed TOI-FA-values > 0
in the corticostriatal pathway (related to bvFTD stage 2), and
those were defined for bvFTD stage 2 who had z-transformed
TOI-FA-values > 0 in the corticospinal tract (related to bvFTD
stage 3). The remaining were categorized into bvFTD stages 3 or
4, depending if their z-transformed TOI-FA-values in the optic
radiation (related to bvFTD stage 4) were> 0 or< 0.
Statistics
Regression Calculations
From the controls’ FA maps for every voxel, a regression line of
FA values depending on the age of the subjects was calculated:
FAi = a
∗
i Age+ bi (2)
i denotes voxel i, and the 3D-matrix of ai was used to calculate
the age-normed FAi values for voxel i in each subject’s FA map.
Scanner Corrections
Differences of FA maps derived from different DTI protocols
were assumed to be approximated by a polynomial approach
(Rosskopf et al., 2015)
y = a0 + a1x+ a2x
2 + . . . + anx
n (3)
where yi and xi were the voxel-FA values of the different samples
at MNI position i; an were the respective coefficients.
The polynomial approach offers the possibility of defining the
differences between FA maps of the different samples (e.g., from
two scan protocols A and B) as
(i) linear shift : a0 6= 0; a1 = 1; an = 0 (n > 1) (4)
(ii) linear regression : a0, a1 6= 0; an = 0 (n > 1) (5)
(iii) higher order differences.
That way, a linear shift 3D correction matrix could be calculated
where each voxel position represents the difference of averaged
FA values of controls (protocol A) and averaged FA values of
controls (protocol B). A linear regression 3D correction matrix
or higher order differences could not be calculated due to
a restricted number of control subjects. NB: The linear shift
approximation a0 6= 0; a1 = 1; an = 0 (n > 1) reveals similar
results as a0 = 0; a1 6= 0; an = 0 (n> 1).
Correlations
For correlation calculations, Pearson’s correlation coefficient R
was used.
RESULTS
Differences in Longitudinal TFAS at the
Group Level
In the follow-up measurements of the 49 bvFTD patients and
the 34 controls, FA differences in the tract systems showed
longitudinal FA reduction in bvFTD patients compared to
controls (Figure 2B). These differences were significant in the
uncinate fascicle (bvFTD-stage 1, p< 0.004), in the corticostriatal
pathway (bvFTD-stage 2, p < 0.008), and in the optic radiation
(bvFTD-stage 4, p < 0.02); no significant differences were found
in the CST (bvFTD-stage 3, p = 0.30) and in the reference
tract (p = 0.51). The grand average, i.e., the average of FA-
values in all stage-related tract systems, showed a significant FA-
reduction for bvFTD patients vs. controls (p < 0.004). These
longitudinal differences were calculated from FA maps after
stereotaxic normalization with data harmonization to a time
interval of 12 months (see Methods section “Data processing
IV”).
The longitudinal tract-related differences in FA values showed
no differences between bvFTD patients of different stages. No
tendency to an accelerated or slowed alteration in a specific
bvFTD-stage could be observed. However, a detailed subgroup
analysis was not possible due to the limited sample sizes in the
subgroups for the single stages.
Tract-Specific Longitudinal FA Decrease
Figure 3A shows that longitudinal FA alterations in the tract
systems uncinate fascicle, corticostriatal pathway, and optic tract
correlate with each other. This is not the case for the CST as the
bvFTD stage 3-related tract system: longitudinal FA alterations
in the CST could be subdivided into two groups with different
correlations with the uncinate fascicle (as well as to the remaining
tract systems). Then, the differences between longitudinal FA
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FIGURE 3 | Longitudinal FA decrease in different tract systems: prominent differences for the CST (bvFTD stage 3). (A) Correlations of FA reductions in bvFTD
patients between tract systems. (B) Squared differences of FA decrease in the CST compared to averaged FA decreases in the other tract systems. A “dichotomous”
behavior was identified: one bvFTD subgroup A (N = 22) with an FA decrease in the CST which is different to the FA decrease in the other stage-related tract
structures (S > 0.011) and the other subgroup (group B, N = 29) with an FA decrease in the CST which is similar to the FA decrease in the other stage-related tract
structures (S < 0.011). The four available pathology results were indicated in red/orange.
alterations in the CST and longitudinal FA alterations in the
remaining tracts were calculated as follows,
S = SQRT[1FA(CST)−61FA(tractX)]2.
tract X = uncinate fascicle, corticostriatal pathway,
optic radiation (6)
Figure 3B shows a discrimination into two groups: Group B
(N = 27) shows longitudinal FA alterations that are the same for
all tract systems, whereas group A (N = 22) shows longitudinal
FA alterations in the CST that are different from longitudinal
FA alterations in the remaining tracts. The separation between
the subgroups was defined by the control group which showed a
variation of the parameter S of 0.011 (µ + σ). The differences in
Figure 3B result from subjects in different stages.
Pathology results from four bvFTD-patients revealed 1 tau-
mutation and 3 TDP43 mutations. The classification of these
pathology cases according to Equation (1) showed the 3 TDP43-
mutations in group A and the tau-mutation in group B.
Whole Brain-Based Spatial
Statistics—WBSS
The voxelwise comparison of FA differences between bvFTD
patients and controls revealed significant differences in the
frontal lobes (Figure 4A); FA-values were linearly corrected to
the identical time interval of 12 months prior to the comparison
at the group level (see Methods section “Data processing IV”).
After correction for scanner differences and age, baseline scans
of 62 bvFTD patients and 47 controls underwent WBSS. WBSS
result patterns demonstrated extensive clusters mainly in the
frontal lobes as well as in the optic radiation and posterior
temporal white matter (Figures 4B,C). A summary of the
resulting clusters is provided in Supplementary Table 1.
The highest significances in differences at the group level
were found in the frontal lobes (p < 0.00002), followed by
clusters reflecting hippocampal involvement (p < 0.0002 and
p < 0.002, respectively), and then significances (p < 0.02) for
alterations including the optic radiation, p-values were corrected
for multiple comparisons. This significance cascade is illustrated
in Figure 4C.
The TFAS-based analysis of tract systems showed a similar
significance pattern compared to WBSS, with the highest
differences of FA values between bvFTD patients and controls in
the uncinate fascicle (p< 0.0000000001) and in the corticostriatal
pathway (p < 0.0000004). In addition, the TFAS-based analysis
was also significant in the optic radiation (p< 0.04), but not in the
CST (p= 0.96) and in the reference tract (p= 0.64; Figure 4D).
bvFTD Staging by TFAS
A categorization into the staging scheme (“bvFTD stage 1” to
“bvFTD stage 4”—Figure 1B; Methods section “Data processing
VI”) was performed by use of the staging scheme (“bvFTD
stage 1” to “bvFTD stage 4”) using the decision algorithm
following Kassubek et al., 2014; the results are summarized in
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FIGURE 4 | Comparison at the group level—bvFTD-patients vs. controls. (A) Whole brain-based spatial statistics (WBSS) of longitudinal alterations in FA maps of 49
bvFTD-patients vs. 34 controls (at FDR corrected p < 0.05). (B) WBSS of FA maps of 62 bvFTD-patients vs. 47 controls (at FDR corrected p < 0.05). (C) Whole
brain-based spatial statistics (WBSS) of FA maps (FDR corrected) in sagittal projectional views for different significances. (D) Significance levels for TFAS of tract
systems corresponding to bvFTD-stages: fasciculus uncinatus (bvFTD stage 1), corticostriatal pathway (bvFTD stage 2), corticospinal tract (CST) (bvFTD stage 3),
optic radiation (bvFTD stage 4), and as the reference path the superior cerebellar peduncle.
Supplementary Table 2. FA values of the uncinate fascicle of
bvFTD patients showed a sensitivity of 81% in the separation
from controls’ FA values. This means that 81% of the baseline
scans could be categorized. The staging categorization was
performed independently for baseline and for follow-up data
following the identical rules. Examples for patients in bvFTD-
stages 1–4 are summarized in Figure 5, showing bvFTD-staging
examples of baseline and follow-up scans, displaying the decrease
in FA values in the respective tract systems. Fifty patients (81%)
could be classified at the baseline scan. Classification was not
possible in the remaining 12 since they showed no abnormalities
in the uncinate fascicle (bvFTD stage 1 related tract). However,
in the follow-up data sample, 42/49 bvFTD patients (86%) could
be classified. Of these, seven patients showed an increase in the
bvFTD stage (Table 3), 35 showed a constant stage, and seven
were not classifiable. One bvFTD patient who had not been
classifiable at baseline could be classified at the follow-up scan,
five showed an increase of one stage, and one showed an increase
of two stages. The tract-related differences in FA values were
distributed over bvFTD stage 1 to bvFTD stage 4, no tract-related
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FIGURE 5 | Individual examples for the staging categorization. Individual cross-sectional examples for the categorization of bvFTD patients into bvFTD stages based
upon deviations of z-transformed FA-values (TFAS) from controls’ values for different bvFTD stages. Left: baseline categorization, Right: categorization at follow-up.
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TABLE 3 | Staging categorization.





not stageable 12 7
∑
62 49
*At baseline and at follow-up, 8 out of 24 bvFTD patients already showed involvement of
the optic radiation.
difference specific to single stage structures could be observed. A
detailed subgroup analysis was not possible due to a low N in the
subgroups for the respective stages. The differences in Figure 2B
occur from subjects in different stages. At baseline and at follow-
up, 8 bvFTD patients that were categorized as bvFTD stage 2
show alterations in tract 4 associated tracts (Table 3).
Comparison to Neuropathology
Neuropathology results were available from four bvFTD-patients.
They revealed one Tau-mutation and three TDP-43 mutations
(Figure 3B). The classification of these cases according to
Equation (1) showed the three TDP-43mutations in groupA, and
the Tau-mutation in group B.
DISCUSSION
In Vivo Imaging of TDP-43 Pathology in
bvFTD
After the development of a concept for patterns of TDP-
43 pathology in bvFTD that showed a possible sequential
progression of pTDP-43 aggregates (Brettschneider et al., 2014),
the task remained to see if in vivo neuroimaging measures might
be identified which were consistent with these proposed patterns
of progression. Here, we adapted the DTI/TOI-based staging
approach (Kassubek et al., 2014), which was developed for the
proposed sequential progression of ALS neuropathology (Braak
et al., 2013), to bvFTD.
Cross Sectional and Longitudinal
Alteration Patterns in bvFTD
The neuroimaging patterns observed in this study reflected
the characteristic damage pattern of frontotemporal structures
cross-sectionally as well as longitudinally. This “classical” finding
has been included in the current definition of the diagnostic
criteria, with one item (III.C.1.) for probable bvFTD reading
as follows: “... imaging results consistent with bvFTD must be
present: frontal and/or anterior temporal atrophy on MRI or
CT” (Rascovsky et al., 2011). Beyond any reasonable doubt, this
atrophy pattern represents the characteristic andmacroscopically
accessible structural imaging finding in bvFTD that can also be
observed by functional radioligand neuroimaging, as also noted
in the revised diagnostic criteria (III.C.2., “frontal and/or anterior
temporal hypoperfusion or hypometabolism on PET or SPECT”;
Rascovsky et al., 2011). There is ample evidence for these findings
from a multitude of neuroimaging studies across modalities, as
confirmed by a recent meta-analysis by use of the anatomical
likelihood estimate method (Schroeter et al., 2014). In the current
study, the WBSS analysis resembled this pattern. Remarkably,
similar DTI changes in the posterior temporal WM have been
reported in bvFTD cross-sectionally and longitudinally (Agosta
et al., 2012; Lam et al., 2014; Mahoney et al., 2015).
Tract Definitions
With the exception of pattern 1, each of the tracts selected
ends in the regions defined where TDP-43 pathology was
reported: pattern 2: corticostriatal/accumbens nucleus; pattern
3: corticospinal tract/spinal cord ventral horn; pattern 4:
optic radiation/primary visual cortex. Granted, for pattern 1
(uncinate fascicle/basal and anterior prefrontal neocortex),
the uncinate fascicle extends further into anteromedial
portions of the temporal lobe; but it is equally clear that, in
bvFTD, neuropathology is present in temporal lobe structures
with the exception of the superior temporal gyrus (The
Lund and Manchester groups, 1994; Brettschneider et al.,
2014). Importantly, it cannot be claimed that the results
presented here confirm TDP-43-based staging, as other staging
schemes/pathological proteins (e.g., tau, SOD1) were not
tested, and it is not known whether these subjects were indeed
TDP-43-positive subjects.
Hypothesis Guided Tract-Based Analysis
Specifically, the TOI-based approach used in this study is
a microstructural measure of correlates of the progressive
pathological process. This technique targets distinct anatomical
tract structures that correlate with the proposed progression
pattern based upon histopathology (Brettschneider et al., 2013)
and are not per se identifiable by mere inspection of MRI
structure and not even by data-driven (perhaps whole-brain
based) computerized analyses. The approach to analyze a
“progression” pattern is longitudinal in nature. As such, the
analysis according to the progression concept—which has been
developed on the basis of cross-sectional postmortem data—
aims at the identification of patterns that can be consistently
found in a diverse group of neurodegenerative disorders, such as
FTLD, each of which entails the aggregation of abnormal protein
inclusions in characteristic patterns and locations (Jucker and
Walker, 2013).
For the complete sample, the highest significance in
discriminating between patients with bvFTD and controls was
observed for the early tract patterns 1 and 2, and the significance
level of the comparisons at the group level was lower the higher
the disease stage at which the corresponding tracts were involved.
The differences in the optic radiation (bvFTD stage 4-related
tract) were significant, although a high variability in the controls
sample was observed. In the longitudinal data with a time interval
of about 12 months, three tract structures showed significant
longitudinal FA decrease.
These results are in a general line of agreement with the
recently proposed neuropathological bvFTD propagation pattern
(Brettschneider et al., 2014). In the staging categorization, seven
bvFTD patients showed a progression of bvFTD stage and 42
bvFTD patients showed a stable bvFTD stage, thus underlining
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the plausibility of the neuroimaging staging concept. This
concept allows for a classification of about 80% of the patients
(compare also Kassubek et al., 2014), and longitudinal assessment
resulted in a lower number of unclassified cases.
LIMITATIONS
The present study is not without limitations. A technical
limitation of this study is the assumption that the alteration
process in FA values is linear, with the consequence of a linear
correction of FA-value differences to the identical time interval
of 12 months prior to the comparison at the group level.
This assumption was a first order approximation and does not
incorporate that data at different clinical severity could cause
changes in DTI measures that are not linear in time. However,
given the lack of a uniform theory about the longitudinal
alterations of FA (and other DTI metrics), FA alterations were
approximated as a linear process in the observed average time
range of about one year.
A further limitation of this method is that intrinsically (due to
a sensitivity< 100%) only between 80 and 90% of the data could
be categorized.
A major limitation of any neuroimaging approach, including
the present one, is the lack of autopsy-confirmed data. Thus,
our TOI-based analysis can provide only a plausible surrogate in
vivo “staging” pattern for the presumed pathology in the bvFTD
cohort studied. The findings require confirmation in longitudinal
autopsy-controlled studies, i.e., to date only four cases have
been confirmed neuropathologically. This number is insufficient
to know with certainty whether the proposed approach works.
Therefore, the results concerning the “dichotomous” behavior
of CST-related FA changes are interpreted as possibilities rather
than as validated results. In this context, one limitation derives
from neuropathological observations that FTLD presenting as
bvFTD showed pTDP-43 pathology in only about 45–50% of
cases, whereas other cases are defined by neuronal inclusions
of the microtubule-associated protein tau or, less frequently,
by aggregates of the RNA-binding protein FUS (Ling et al.,
2013). To date, there is no in vivo test that makes it possible to
reliably differentiate FTLD-TDP from FTLD-tau or—FUS, and
the cohort in the present study most likely included cases with
mixed underlying protein pathologies, for which scant autopsy
data were available. Therefore, sequential fiber tract involvement,
as observed here, is likely to reflect progression of disease
pathology in bvFTD cases in general, although our results may
or may not be specific to cases with pTDP-43 pathology. In a
recent autopsy study of 21 individuals with Pick’s disease (PiD),
tau lesions (FTDL-tau) were detected in some of the same regions
as the pTDP-43 pathology in pTDP-43 bvFTD cases but not
always at the same phases, e.g., orbital gyri, superior and middle
temporal gyri (PiD phase 1, one case), middle frontal and anterior
cingulate gyri, striatum, primary somatosensory neocortex (PiD
phase 2, three cases), agranular motor neocortex, precerebellar
nuclei of the brainstem (PiD phase 3), primary visual neocortex
(PiD phase 4) (Irwin et al., 2016).
The previous publication on which the present neuroimaging
study is based referred to “patterns” rather than “stages” of TDP-
43 pathology in bvFTLD, i.e., it was not intended to serve as
a neuropathological staging system for all FTLD-TDP and it
excluded cases with PiD (Brettschneider et al., 2014). TheN = 39
cases with bvFTD examined by Brettschneider et al., 2014 had
varied genetic backgrounds and differed with respect to their
clinical phenotypes; nevertheless, they displayed similar patterns
of TDP-43 pathology in the end phase of the disease at autopsy
(Brettschneider et al., 2014). Within the pTDP-43-associated
variant itself, a differentiation between the dendritic/neuritic
(nFTLD) and pericaryal/cytoplasmic (cFTLD) types on clinical
grounds is still not possible (Brettschneider et al., 2014).Whereas,
cases with nFTLD pathology were reported to show widespread
and severe neocortical involvement from orbitofrontal areas
along the entire convexity of the brain that frequently reached
the occipital cortex, cFTLD cases by contrast showed less severe
neocortical involvement (Brettschneider et al., 2014). Thus, it
is difficult to speculate here about the possible impact of the
cFTLD/nFTLD proportion of our sample on the DTI results.
However, to the extent that none of the cases in the present
cohort showed deficits associated with motor neuron disease,
and inasmuch as the cFTLD type pathology appears to be more
closely related to ALS than the nFTLD type—cFTLD cases are
not only much more likely to have clinical signs of motor neuron
disease (p < 0.001, Brettschneider et al., 2014) but also a shorter
survival period—the lack of involvement on the part of the CST
might not be not entirely surprising.
A potential approach to this open question might be derived
from the longitudinal data of this study: The “dichotomous”
behavior of CST-related FA changes could be interpreted as an
indicator for the presence of pTDP-43 pathology of the cFTLD
type in the sample with an FA decrease in CST that is different
from the FA decrease in the other stage-related tract structures.
This interpretation that the CST may differentiate between these
neuropathological subtypes, however, remains speculative and is
data-driven by the “dichotomous” results in the CST. As such, it
will require further confirmation by autopsy studies or needs to
be supported by more longitudinal data sets.
The mean disease duration differed between the three sites.
As a consequence the longitudinal alterations were calculated as
differences between two scans so that they were independent of
the scanner type. In that respect, differences in average disease
duration between centers did not affect the analysis and the
bvFTD group can be considered as one group with an average
disease duration of 5 ± 4 years. However, no correlation of the
staging with clinical/behavioral severitymeasures could be found.
Behavioral severity measures were not available for many data
sets; thus, this correlation could not be calculated.
Hyperphosphorylated Tau Pathology
According to a recent autopsy-based study, hyperphosphorylated
tau pathology was present in 98% of the 296 cognitively
unimpaired subjects ranging from age 50 to 102 years of age;
Aβ was seen in 50%, TDP-43 in 36%, and α-synuclein in 19% of
the subjects (Elobeid et al., 2016). Thus, it is not unreasonable
to assume that the individuals in the present cohort could
have mixed pathologies. On the other hand, it is also true that
most cases with autopsy-confirmed bvFTD do not display high
AD-associated NFT and Aβ stages or α-synuclein Parkinson’s
disease-related stages (Brettschneider et al., 2014; Perry et al.,
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2017). Moreover, although our cases with bvFTD may have
varied genetic backgrounds, Brettschneider et al., 2014 showed
that even such individuals revealed similar patterns of TDP-43
pathology at end stage disease upon postmortem examination.
Even where somewhat different white matter profiles were seen
to be associated with genetic sub-groups of bvFTD (e.g., MAPT
and C9ORF72 mutations, the main point is that bvFTD can
be distinguished from AD (Mahoney et al., 2014). As such, we
do not believe the presence of concurrent pathological proteins
in our cohort would have had a major impact on the present
neuroimaging findings.
Summary
In summary, the hypothesis-driven analysis of the
neuropathologically-defined progression pattern with the
in vivo TOI-based technique was applied to the bvFTD sample
and suggested a characteristic pattern of damage to the involved
major white matter pathways both cross-sectionally and
longitudinally.
It has already been demonstrated that progressive regional
accumulation of pTDP-43 inclusions in ALS reflects sequential
involvement of white matter fiber tracts of the central
nervous system (Kassubek et al., 2014, 2017; Müller et al.,
2016). While no direct neuroimaging marker for pTDP-
43 exists at present, several earlier neuropathological studies
have emphasized the close correlation between the severity
of pTDP-43 aggregation and neuro-axonal loss (Geser et al.,
2008, 2009). Therefore, this study is interpreted as a first
attempt to apply DTI—which has already successfully proven
to serve as a marker for microstructural integrity in pTDP-43
related neurodegeneration in ALS (Kassubek et al., 2017)—as a
possible marker for microstructural integrity to bvFTD. The DTI
investigation of microstructural integrity is a distinct technique
to regional volumetric analysis which measures directly regional
atrophy and, in that manner, could serve as a complementary
neuroimaging marker.
This approach might have the potential for future
use in the work-up of individual patients, thereby also
potentially enlarging the spectrum of non-invasive markers
as a neuroimaging-based read-out for clinical studies
and supporting the identification of patients who might
be eligible for trials targeted at treating the specific
histopathologic abnormalities causing FTLD (Grossman,
2010).
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